Rivaroxaban for preventing adverse outcomes after acute management of acute coronary
KEYWORDS: rivaroxaban, patients, aspirin, treatment, committee, coronary, company, acute, erg, trial, acute coronary, syndrome, coronary syndrome, events, dose

on the results for the 2.5 mg twice-daily dose because this is the licensed dose. Table 2 Effect of rivaroxaban compared with placebo on the primary efficacy end point and components (licensed population, mITT analysis [excluding 3 sites]) for all strata (n=12,353) 2.5 mg Rivaroxaban bd versus 5 mg Rivaroxaban bd versus Combined rivaroxaban dose versus All strata n=12,353 placebo placebo placebo HR 0.80 HR 0.79 HR 0.79 Primary end 95% CI 0.68 to 0.94 95% CI 0.67 to 0.93 95% CI 0.69 to 0.91 point p=0.007 p=0.004 p=0.001 HR 0.55 HR 0.89 HR 0.72 CV death 95% CI 0.41 to 0.74 95% CI 0.69 to 1.15 95% CI 0.57 to 0.90 p<0.001 p=0.360 p=0.004 2.5 mg Rivaroxaban bd versus 5 mg Rivaroxaban bd versus Combined rivaroxaban dose versus All strata n=12,353 placebo placebo placebo HR 0.88 HR 0.75 HR 0.81 MI 95% CI 0.72 to 1.08 95% CI 0.61 to 0.92 95% CI 0.68 to 0.97 p=0.215 p=0.007 p=0.021 HR 1.23 HR 1.38 HR 1.30 Stroke 95% CI 0.75 to 2.02 95% CI 0.85 to 2.24 95% CI 0.85 to 2.01 p=0.403 p=0.190 p=0.225 Abbreviations: bd, twice daily; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; MI, myocardial infarction;
